NASDAQ:LGND - Ligand Pharmaceuticals Stock Price, Forecast & News

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) released its quarterly earnings data on Tuesday, November, 5th. The biotechnology company reported $0.49 earnings per share for the quarter, missing the consensus estimate of $0.61 by $0.12. The biotechnology company earned $24.81 million during the quarter, compared to the consensus estimate of $22.49 million. Ligand Pharmaceuticals had a net margin of 388.69% and a return on equity of 7.47%. The company's revenue for the quarter was down 45.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.32 earnings per share. View Ligand Pharmaceuticals' Earnings History.

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Ligand Pharmaceuticals.

Ligand Pharmaceuticals will be holding an earnings conference call on Thursday, February 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Ligand Pharmaceuticals updated its FY19 earnings guidance on Tuesday, November, 5th. The company provided EPS guidance of ~$3.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.25. The company issued revenue guidance of ~$118 million, compared to the consensus revenue estimate of $119.01 million.

4 brokers have issued 1-year price targets for Ligand Pharmaceuticals' stock. Their forecasts range from $132.00 to $214.00. On average, they anticipate Ligand Pharmaceuticals' stock price to reach $166.50 in the next twelve months. This suggests a possible upside of 85.6% from the stock's current price. View Analyst Price Targets for Ligand Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ligand Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ligand Pharmaceuticals.

Media headlines about LGND stock have trended somewhat positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ligand Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Ligand Pharmaceuticals.

Some companies that are related to Ligand Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Ligand Pharmaceuticals investors own include Jazz Pharmaceuticals (JAZZ), NVIDIA (NVDA), Micron Technology (MU), Alibaba Group (BABA), Illumina (ILMN), Netflix (NFLX), Gilead Sciences (GILD), AbbVie (ABBV), Baidu (BIDU) and Intel (INTC).

Ligand Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Woodstock Corp (0.41%), Summit Creek Advisors LLC (0.40%), Louisiana State Employees Retirement System (0.02%), State of Alaska Department of Revenue (0.02%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John L Lamattina, John W Kozarich, Matthew E Korenberg, Matthew W Foehr, Stephen L Sabba, Sunil Patel and Todd C Davis. View Institutional Ownership Trends for Ligand Pharmaceuticals.

LGND stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Louisiana State Employees Retirement System and Summit Creek Advisors LLC. View Insider Buying and Selling for Ligand Pharmaceuticals.

LGND stock was acquired by a variety of institutional investors in the last quarter, including Woodstock Corp and Nisa Investment Advisors LLC. Company insiders that have bought Ligand Pharmaceuticals stock in the last two years include Jason Aryeh, John L Higgins and Sunil Patel. View Insider Buying and Selling for Ligand Pharmaceuticals.

Shares of LGND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LGND stock can currently be purchased for approximately $89.69.

Ligand Pharmaceuticals has a market capitalization of $1.57 billion and generates $251.45 million in revenue each year. The biotechnology company earns $143.32 million in net income (profit) each year or $6.28 on an earnings per share basis. Ligand Pharmaceuticals employs 116 workers across the globe.View Additional Information About Ligand Pharmaceuticals.

The official website for Ligand Pharmaceuticals is http://www.ligand.com/.

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]